BrightHeart, a Paris-based MedTech company developing artificial intelligence software for prenatal ultrasound, has closed an €11 million Series A financing round. The investment will support U.S. market entry, continued expansion across Europe, and further development of its AI platform for expert-level fetal screening.
The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and existing investor Sofinnova Partners. The syndicate also includes clinicians and MedTech entrepreneurs, among them Professor Laurent Salomon, former president of the International Society of Ultrasound in Obstetrics and Gynecology.
Scaling expert-level AI for routine prenatal care
BrightHeart develops AI software that supports clinicians during prenatal ultrasound exams, with a particular focus on complex organs such as the fetal heart. Its B-Right AI Platform integrates directly into standard ultrasound workflows, helping OB-GYNs perform more complete exams, evaluate images faster, and improve diagnostic confidence without adding complexity to daily practice.
The company aims to raise the standard of care in prenatal imaging by making expert-level screening more widely accessible, supporting earlier and more accurate detection of congenital heart defects and other conditions.
Advertisement
Strong regulatory and clinical momentum
The Series A follows a period of significant progress for BrightHeart. In 2025, the company secured five FDA clearances, established collaborations with leading academic medical centers, and published two peer-reviewed clinical studies in Obstetrics & Gynecology. According to the company, this makes BrightHeart the only player in its segment with peer-reviewed clinical evidence supporting its technology.
This regulatory and clinical foundation positions the platform for broader international deployment as demand grows for AI-driven diagnostic support in prenatal care.
Investor confidence in global expansion
According to BrightHeart CEO Cécile Dupont, the new funding enables the company to accelerate its mission of embedding AI as a standard component of prenatal ultrasound exams, improving outcomes for families while simplifying workflows for healthcare professionals.
Investors highlighted the company’s combination of clinical depth, workflow integration, and scalability as key differentiators. Representatives from Odyssée Venture and GO Capital pointed to BrightHeart’s potential to become a reference platform in prenatal ultrasound as AI adoption increases across healthcare systems.
The participation of the Mussallem CHD Alliance reflects the platform’s relevance for improving early detection of congenital heart defects, an area where timing and diagnostic accuracy are critical for patient outcomes.
About BrightHeart
BrightHeart is a medical device company developing AI-powered software for prenatal ultrasound. Its FDA-cleared solutions provide real-time guidance throughout the ultrasound exam, supporting expert-level fetal heart screening, full anatomical tracking, and efficient clinical evaluations. Designed for seamless integration into existing workflows, BrightHeart’s technology aims to improve diagnostic accuracy, reduce errors, and enhance efficiency in prenatal imaging worldwide.
